FCF Healthcare & Life Sciences
Venture Capital Monitor
-
Europe

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous slide
Next slide

As of the end of December 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 8,949m
  • Biotech received 42% of the total investment volume (+1% compared to the previous month)
  • Oncology dominates as the top indication in Biotech
  • Freya Biosciences (Denmark) has the highest transaction volume of EUR 35m in December, followed by Laza Medical (Switzerland) EUR 33m and Eligo Biosciences (France) EUR 30m
  • The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Jeito (France) and Forbion (Netherlands)
  • Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous slide
Next slide

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS